Menu Fermer

CAPSID INHIBITORS

 Mutations associated with resistanceMutations associated with « possible resistance »
LEN
L56I [1]
M66I [1]
Q67H [1]
K70N/R/S [1, 2]
N74D/S [1]
T107N [1]
 

LEN : lenacapavir

1/ Yant SR, Mulato A, Hansen D et al. In vitro resistance profile of GS-6207, a first-in-class picomolar HIV capsid inhibitor in clinical development as a novel long-acting antiretroviral agent. Tenth IAS Conference on HIV Science, Mexico City, Mexico, 2019. Poster TUPEA075.

2/ Molina JM Segal-Maurer S, Stellbrink HJ et al. Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study) .IAS 2021,abstract OALX01LB02.